PROGESTERONE RECEPTOR NEGATIVE
Clinical trials for PROGESTERONE RECEPTOR NEGATIVE explained in plain language.
Never miss a new study
Get alerted when new PROGESTERONE RECEPTOR NEGATIVE trials appear
Sign up with your email to follow new studies for PROGESTERONE RECEPTOR NEGATIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immune booster before chemo shows promise for tough breast cancer
Disease control OngoingThis study tests whether giving two immunotherapy drugs (decitabine and pembrolizumab) before standard chemotherapy can help the immune system attack HER2-negative breast cancer more effectively. About 46 adults with locally advanced disease will receive a short course of these d…
Matched conditions: PROGESTERONE RECEPTOR NEGATIVE
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jul 02, 2026 07:00 UTC
-
New combo therapy targets Hard-to-Treat recurrent cancers
Disease control OngoingThis early-phase trial tests two different drug combinations—olaparib plus vistusertib, or olaparib plus capivasertib—in people with recurrent endometrial, triple-negative breast, ovarian, primary peritoneal, or fallopian tube cancer. The main goal is to find the safest dose and …
Matched conditions: PROGESTERONE RECEPTOR NEGATIVE
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for tough breast cancer: which chemo works best after surgery?
Disease control OngoingThis study tests whether platinum-based chemotherapy (cisplatin or carboplatin) works better than capecitabine in people with a certain type of triple-negative breast cancer that remains after initial chemotherapy and surgery. About 415 participants with stage II-III breast cance…
Matched conditions: PROGESTERONE RECEPTOR NEGATIVE
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could adding carboplatin to chemo keep triple-negative breast cancer away?
Disease control OngoingThis phase 3 trial tests whether adding the drug carboplatin to standard chemotherapy (doxorubicin, cyclophosphamide, and paclitaxel) helps prevent triple-negative breast cancer from coming back. About 782 patients with high-risk or node-positive disease are participating. The st…
Matched conditions: PROGESTERONE RECEPTOR NEGATIVE
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for aggressive breast cancer: targeted combo before surgery
Disease control OngoingThis study tests whether adding the drug panitumumab to standard chemotherapy helps shrink tumors more effectively in people with a rare and aggressive type of breast cancer called triple-negative inflammatory breast cancer. About 42 participants will receive chemotherapy before …
Matched conditions: PROGESTERONE RECEPTOR NEGATIVE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New chemo combo aims to shrink aggressive breast cancer before surgery
Disease control OngoingThis phase II trial is testing whether giving two chemotherapy drugs, carboplatin and nab-paclitaxel, before surgery can improve outcomes for people with locally advanced or inflammatory triple negative breast cancer. The goal is to see if this approach increases the rate of comp…
Matched conditions: PROGESTERONE RECEPTOR NEGATIVE
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New Vaccine-Immunotherapy combo targets multiple cancers in early trial
Disease control OngoingThis phase 1 trial tests a vaccine (p53MVA) that trains the immune system to attack cancer cells with a p53 mutation, given together with the immunotherapy drug pembrolizumab (Keytruda). The study includes 11 people with advanced solid tumors like lung, head and neck, liver, kidn…
Matched conditions: PROGESTERONE RECEPTOR NEGATIVE
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Immunotherapy shows promise in controlling advanced breast cancer after chemo
Disease control OngoingThis study tested the drug pembrolizumab in 71 people with advanced inflammatory or triple-negative breast cancer that had spread or returned. Participants had already responded to chemotherapy. The goal was to see if pembrolizumab could keep the cancer from growing for at least …
Matched conditions: PROGESTERONE RECEPTOR NEGATIVE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New scan could reveal which breast cancer patients will respond to hormone therapy
Diagnosis OngoingThis phase 2 trial tests whether a PET scan using a radioactive form of estrogen (FES) can predict how well endocrine therapy works in 99 women with newly diagnosed metastatic breast cancer. The scan lights up cancer cells that have estrogen receptors, helping doctors see if the …
Matched conditions: PROGESTERONE RECEPTOR NEGATIVE
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Jul 01, 2026 00:00 UTC
-
Can new scans predict chemo success in Triple-Negative breast cancer?
Knowledge-focused OngoingThis early-phase trial is testing whether two advanced imaging techniques—DCE-MRI and molecular breast imaging (MBI)—can accurately assess how triple-negative breast cancer tumors respond to chemotherapy. About 96 patients will undergo these scans before, during, and after treatm…
Matched conditions: PROGESTERONE RECEPTOR NEGATIVE
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Genetic counseling by phone may ease cancer fears in High-Risk women
Knowledge-focused TerminatedThis study looks at whether watching an online genetics video, with or without phone counseling from a genetic counselor, can reduce the stress women feel about their cancer risk. It involves 5,200 women aged 30 or older who have had triple-negative breast cancer and still have a…
Matched conditions: PROGESTERONE RECEPTOR NEGATIVE
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC